Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Internal Medicine (Tokyo, Japan)|November 1, 2005
Analysis of 645 patients with primary hyperparathyroidism with special references to cholelithiasisPetr Don Broulik, Tomas Haas, Svaiopiak Adámek
The American Journal of Cardiology|September 3, 2004
Repeatability of noninvasive surrogates of endothelial functionJan Malik, Dan Wichterle, Tomas Haas, et al.
Transplantation|November 19, 2004
Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label studyBjörn Nashan, John Curtis, Claudio Ponticelli, et al.
The Canadian Journal of Cardiology|May 29, 2003
Intima-media thickness of the common carotid artery is the significant predictor of angiographically proven coronary artery diseaseRobert Holaj, Jiri Spacil, Jan Petrasek, et al.
Saudi Medical Journal|October 5, 2007
Standard surgical versus percutaneous dilatational tracheostomy in intensive care patientsJindrich Lukas, Jaroslava Duskova, David Lukas, et al.
The American Journal of Cardiology|July 31, 2003
Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemiaVojtech Melenovsky, Dan Wichterle, Jan Simek, et al.
Experimental Hematology & Oncology|December 10, 2013
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparisonJames Signorovitch, Elyse Swallow, Evan Kantor, et al.
Endocrine Research|December 20, 2002
Soluble leptin receptor levels in patients with anorexia nervosaJarmila Krizova, Hana Papezova, Denisa Haluzikova, et al.
The Oncologist|April 5, 2011
Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapyJennifer L Beaumont, Zeeshan Butt, Jeanfrancois Baladi, et al.
Annals of the New York Academy of Sciences|May 11, 2013
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseasesDavid Lebwohl, Ozlem Anak, Tarek Sahmoud, et al.
Pageof 2